title: Comparison of topically applied flurbiprofen or bromfenac ophthalmic solution on post-operative ocular hypertension in canine patients following cataract surgery.
abstract: OBJECTIVE
  To compare the prevalence and kinetics of ocular hypertension after routine cataract extraction when using a predominately COX-2 inhibitor (bromfenac) versus a predominately COX-1 inhibitor (flurbiprofen) in combination with a topical corticosteroid.
  
  
  METHODS
  Patients undergoing unilateral or bilateral cataract surgery were randomly assigned to receive flurbiprofen or bromfenac at the day of surgery and continued for 6 weeks postoperatively, along with topical neo poly dexamethasone. No systemic nonsteroidal anti-inflammatory medications were administered before or after surgery. Intraocular pressure was monitored pre and postoperatively. When an IOP of >25 mmHg was detected, therapeutic intervention was performed.
  
  
  RESULTS
  Eyes in both treatment groups showed a similar IOP profile with the highest mean IOP occurring two hours postsurgery and slowly declining during the next 6 weeks. However, eyes receiving bromfenac had a higher mean IOP at 2 h post-op (22.1 mmHg) than eyes receiving flurbiprofen (18.8 mmHg) and a slower decrease in IOP in the weeks after surgery. Over the course of the study, a higher percentage of eyes receiving bromfenac had therapy discontinued over concerns of elevated IOP compared to eyes receiving flurbiprofen (bromfenac 23.1% and flurbiprofen 9.8%). On average, the risk of having elevated intraocular pressure with bromfenac is 1.04 times higher than with flurbiprofen.
  
  
  CONCLUSIONS
  Elevated postoperative IOP was observed in both treatment groups; however, bromfenac-treated eyes were more likely to require intervention for elevated IOP.
authors.affiliation: Animal Eye Care, 197 Defense Highway, Suite 101, Annapolis, MD, 21401, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Lu
authors.affiliation: Animal Eye Care, 197 Defense Highway, Suite 101, Annapolis, MD, 21401, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: English
authors.affiliation: Animal Eye Care, 197 Defense Highway, Suite 101, Annapolis, MD, 21401, USA.
authors.forename: Brad
authors.initials: B
authors.lastname: Nadelstein
authors.affiliation: Animal Eye Care, 197 Defense Highway, Suite 101, Annapolis, MD, 21401, USA.
authors.forename: Anne
authors.initials: A
authors.lastname: Weigt
authors.affiliation: Animal Eye Care, 197 Defense Highway, Suite 101, Annapolis, MD, 21401, USA.
authors.forename: Andrew
authors.initials: A
authors.lastname: Berdoulay
authors.affiliation: Animal Eye Care, 197 Defense Highway, Suite 101, Annapolis, MD, 21401, USA.
authors.forename: Dan
authors.initials: D
authors.lastname: Binder
authors.affiliation: Animal Eye Care, 197 Defense Highway, Suite 101, Annapolis, MD, 21401, USA.
authors.forename: Esther
authors.initials: E
authors.lastname: Ngan
mesh_terms: D060433:Administration, Ophthalmic; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D001577:Benzophenones / Q000008:administration & dosage / Q000009:adverse effects*; D001969:Bromobenzenes / Q000008:administration & dosage / Q000009:adverse effects*; D002387:Cataract Extraction / Q000009:adverse effects / Q000662:veterinary*; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D005480:Flurbiprofen / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D009798:Ocular Hypertension / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology*; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D011183:Postoperative Complications / Q000139:chemically induced*; D015995:Prevalence; D011446:Prospective Studies
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001577:Benzophenones; D001969:Bromobenzenes; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D009883:Ophthalmic Solutions; D005480:Flurbiprofen; C053083:bromfenac
keywords: bromfenac; cataract; dogs; flurbiprofen; phacoemulsification; post-operative hypertension